WO1997035841A3 - Method for obtaining pure enantiomers of a pyridazinone derivative - Google Patents

Method for obtaining pure enantiomers of a pyridazinone derivative Download PDF

Info

Publication number
WO1997035841A3
WO1997035841A3 PCT/FI1997/000196 FI9700196W WO9735841A3 WO 1997035841 A3 WO1997035841 A3 WO 1997035841A3 FI 9700196 W FI9700196 W FI 9700196W WO 9735841 A3 WO9735841 A3 WO 9735841A3
Authority
WO
WIPO (PCT)
Prior art keywords
pure enantiomers
obtaining pure
pyridazinone derivative
methyl
end product
Prior art date
Application number
PCT/FI1997/000196
Other languages
French (fr)
Other versions
WO1997035841A2 (en
Inventor
Mika Timmerbacka
Jorma Lehtonen
Veli Pekka Tanninen
Esa Muttonen
Jukka Kaukonen
Riikka Hyppoelae
Original Assignee
Orion Yhtymae Oy
Mika Timmerbacka
Jorma Lehtonen
Veli Pekka Tanninen
Esa Muttonen
Jukka Kaukonen
Riikka Hyppoelae
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL97364220A priority Critical patent/PL190574B1/en
Priority to SK1316-98A priority patent/SK285362B6/en
Application filed by Orion Yhtymae Oy, Mika Timmerbacka, Jorma Lehtonen, Veli Pekka Tanninen, Esa Muttonen, Jukka Kaukonen, Riikka Hyppoelae filed Critical Orion Yhtymae Oy
Priority to PL97329068A priority patent/PL189963B1/en
Priority to PL97364219A priority patent/PL190573B1/en
Priority to US09/155,294 priority patent/US6180789B1/en
Priority to SI9730713T priority patent/SI0894087T1/en
Priority to SK5035-2005A priority patent/SK285363B6/en
Priority to HU9904150A priority patent/HU227541B1/en
Priority to DK97914347T priority patent/DK0894087T3/en
Priority to NZ332010A priority patent/NZ332010A/en
Priority to MXPA98007851A priority patent/MXPA98007851A/en
Priority to BR9708353A priority patent/BR9708353A/en
Priority to EP97914347A priority patent/EP0894087B1/en
Priority to AT97914347T priority patent/ATE299867T1/en
Priority to JP53406397A priority patent/JP4179630B2/en
Priority to CA002250062A priority patent/CA2250062C/en
Priority to DE69733748T priority patent/DE69733748T2/en
Priority to SK5004-2006A priority patent/SK285364B6/en
Priority to AU21626/97A priority patent/AU715887B2/en
Publication of WO1997035841A2 publication Critical patent/WO1997035841A2/en
Publication of WO1997035841A3 publication Critical patent/WO1997035841A3/en
Priority to NO19984487A priority patent/NO312193B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

A method for preparing optically substantially pure (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile from racemic 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone intermediate is described. The end product is useful as a cardiotonic agent. A novel crystalline polymorphic form of the end product is also described.
PCT/FI1997/000196 1996-03-27 1997-03-27 Method for obtaining pure enantiomers of a pyridazinone derivative WO1997035841A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
CA002250062A CA2250062C (en) 1996-03-27 1997-03-27 Method for obtaining pure enantiomers of a pyridazinone derivative
NZ332010A NZ332010A (en) 1996-03-27 1997-03-27 Method for obtaining a pure (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile enantiomers of a pyridazinone derivative
PL97329068A PL189963B1 (en) 1996-03-27 1997-03-27 Method of obtaining pure enantiomers of a pyridazione derivative
PL97364219A PL190573B1 (en) 1996-03-27 1997-03-27 Method for obtaining an enantiomer of (-)6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2h)pyridazinone
US09/155,294 US6180789B1 (en) 1996-03-27 1997-03-27 Method for obtaining pure enantiomers of a pyridazinone derivative
SI9730713T SI0894087T1 (en) 1996-03-27 1997-03-27 Method for obtaining pure enantiomers of a pyridazinone derivative
SK5035-2005A SK285363B6 (en) 1996-03-27 1997-03-27 Method for optical resolution of racemic 6-(4-aminophenyl)- 4,5dihydro-5-methyl-3(2H)-pyridazinone to enantiomers
HU9904150A HU227541B1 (en) 1996-03-27 1997-03-27 Method for obtaining pure enantiomers of a pyridazinone derivative
BR9708353A BR9708353A (en) 1996-03-27 1997-03-27 Methods for obtaining pure enanci of a pyridazinone derivative
PL97364220A PL190574B1 (en) 1996-03-27 1997-03-27 Optically substantially pure polimorphic i enantiomer (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile and method for obtaining some
MXPA98007851A MXPA98007851A (en) 1996-03-27 1997-03-27 Method for obtaining pure enantiomers of a pyridazinone derivative.
DK97914347T DK0894087T3 (en) 1996-03-27 1997-03-27 Process for obtaining pure enantiomers of a pyridazinone derivative
EP97914347A EP0894087B1 (en) 1996-03-27 1997-03-27 Method for obtaining pure enantiomers of a pyridazinone derivative
AT97914347T ATE299867T1 (en) 1996-03-27 1997-03-27 METHOD FOR OBTAINING PURE ENANTIOMERS OF A PYRIDAZINONE DERIVATIVE
JP53406397A JP4179630B2 (en) 1996-03-27 1997-03-27 Method for obtaining pure enantiomers of pyridazinone derivatives
SK1316-98A SK285362B6 (en) 1996-03-27 1997-03-27 Crystalline polymorphous form I of (-)-[[4-(1,4,5,6-tetrahydro-4- methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile and process for preparing thereof
DE69733748T DE69733748T2 (en) 1996-03-27 1997-03-27 METHOD FOR OBTAINING PURE ENANTIOMERS OF A PYRIDAZINONE DERIVATIVES
SK5004-2006A SK285364B6 (en) 1996-03-27 1997-03-27 Method for preparing pure enantiomers of pyridazinone derivative
AU21626/97A AU715887B2 (en) 1996-03-27 1997-03-27 Method for obtaining pure enantiomers of a pyridazinone derivative
NO19984487A NO312193B1 (en) 1996-03-27 1998-09-25 Process for the preparation of optically substantially pure enantiomers of a pyridazinone derivative, process for the optical resolution of a pyridazinone derivative, crystalline polymorphic form of a pyridazinone derivative and a process for obtaining

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9606474.6 1996-03-27
GBGB9606474.6A GB9606474D0 (en) 1996-03-27 1996-03-27 Method for obtaining pure enantiomers of a pyridazinone derivative

Publications (2)

Publication Number Publication Date
WO1997035841A2 WO1997035841A2 (en) 1997-10-02
WO1997035841A3 true WO1997035841A3 (en) 1998-01-22

Family

ID=10791141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI1997/000196 WO1997035841A2 (en) 1996-03-27 1997-03-27 Method for obtaining pure enantiomers of a pyridazinone derivative

Country Status (23)

Country Link
US (1) US6180789B1 (en)
EP (3) EP1619186B1 (en)
JP (3) JP4179630B2 (en)
AT (3) ATE299867T1 (en)
AU (1) AU715887B2 (en)
BR (1) BR9708353A (en)
CA (1) CA2250062C (en)
CZ (3) CZ295002B6 (en)
DE (2) DE69739858D1 (en)
DK (2) DK2143715T3 (en)
ES (3) ES2343525T3 (en)
GB (1) GB9606474D0 (en)
HU (1) HU227541B1 (en)
MX (1) MXPA98007851A (en)
NO (1) NO312193B1 (en)
NZ (1) NZ332010A (en)
PL (3) PL190573B1 (en)
PT (3) PT894087E (en)
SI (2) SI2143715T1 (en)
SK (3) SK285362B6 (en)
TR (1) TR199801921T2 (en)
WO (1) WO1997035841A2 (en)
ZA (1) ZA972729B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606474D0 (en) * 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
FI973804A (en) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Oral compositions of levosimendan
FI105389B (en) * 1998-04-23 2000-08-15 Orion Yhtymae Oyj Procedure for monitoring the tolerance of levosimendan administration
FI104718B (en) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4- (2-Azido-3-methyl-5-oxotetrahydrofuran-2-yl) phenyl] hydrazono] propanedonitrile for use as reference substance in the analysis of batches of levosimendan
US5905078A (en) * 1998-06-19 1999-05-18 Orion Corporation Use of a pyridazinone derivative
FI109659B (en) 1999-09-10 2002-09-30 Orion Yhtymae Oyj Pharmaceutical solutions of levosimendan
WO2008019055A2 (en) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd. Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline
JP5747030B2 (en) 2009-07-14 2015-07-08 シプラ・リミテッド Process for producing levosimendan and intermediate used in the process
JP5482926B2 (en) * 2011-02-28 2014-05-07 株式会社リコー Transmission management device
CN103554033A (en) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 Splitting method for despinner (+/-)-6-(4-aminophenyl)-4, 5-dihydro-5-methyl-3(2H)-pyridazinone
CN103554032A (en) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 Preparation method of high-optical-purity (-)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone
ITMI20132185A1 (en) * 2013-12-23 2015-06-24 Edmond Pharma Srl POLIMORFI DI LEVOSIMENDAN
EP3424908A1 (en) * 2017-07-07 2019-01-09 Melody Healthcare Pvt. Ltd. Process for preparation of levosimendan
US11760730B2 (en) * 2021-01-11 2023-09-19 Navinta, Llc Process for the preparation of high purity Levosimendan

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3857889A (en) * 1968-08-06 1974-12-31 Ici Ltd Isolation process
EP0383449A2 (en) * 1989-02-11 1990-08-22 Orion-Yhtymà„ Oy Pyridazinone derivatives and processes for preparing the same
WO1992012135A1 (en) * 1991-01-03 1992-07-23 Orion-Yhtymä Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU581324B2 (en) 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
GB9606474D0 (en) * 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
FI973804A (en) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Oral compositions of levosimendan

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3857889A (en) * 1968-08-06 1974-12-31 Ici Ltd Isolation process
EP0383449A2 (en) * 1989-02-11 1990-08-22 Orion-Yhtymà„ Oy Pyridazinone derivatives and processes for preparing the same
WO1992012135A1 (en) * 1991-01-03 1992-07-23 Orion-Yhtymä Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOWSON W ET AL: "Synthesis and biological activity of the four stereoisomers of 6-[4-[3-[[2-hydroxy-3-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]propyl] amino]-propionamido]phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone, a combined vasodilator and.beta.-adrenoceptor antagonist", J. MED. CHEM. (JMCMAR,00222623);88; VOL.31 (2); PP.352-6, SMITH KLINE AND FRENCH RES. LTD.;HERTFORDSHIRE; AL6 9AR; UK (GB), XP002047258 *

Also Published As

Publication number Publication date
DE69739858D1 (en) 2010-06-02
HUP9904150A2 (en) 2000-09-28
CZ304198A3 (en) 1999-03-17
DE69733748D1 (en) 2005-08-25
BR9708353A (en) 1999-08-03
HUP9904150A3 (en) 2000-11-28
CA2250062C (en) 2006-11-14
CZ295001B6 (en) 2005-05-18
EP2143715A1 (en) 2010-01-13
DK0894087T3 (en) 2005-09-19
JP2000515492A (en) 2000-11-21
SI0894087T1 (en) 2005-10-31
PT894087E (en) 2005-09-30
PL190573B1 (en) 2005-12-30
SK285364B6 (en) 2006-11-03
CZ294964B6 (en) 2005-04-13
EP0894087B1 (en) 2005-07-20
DE69733748T2 (en) 2006-04-20
EP0894087A2 (en) 1999-02-03
US6180789B1 (en) 2001-01-30
AU715887B2 (en) 2000-02-10
WO1997035841A2 (en) 1997-10-02
CA2250062A1 (en) 1997-10-02
SK285362B6 (en) 2006-11-03
JP2008179645A (en) 2008-08-07
JP2011236251A (en) 2011-11-24
MXPA98007851A (en) 2006-06-07
TR199801921T2 (en) 1998-12-21
JP5277295B2 (en) 2013-08-28
PL189963B1 (en) 2005-10-31
JP4825825B2 (en) 2011-11-30
DK2143715T3 (en) 2011-12-05
ES2343525T3 (en) 2010-08-03
SI2143715T1 (en) 2012-01-31
ZA972729B (en) 1997-10-30
GB9606474D0 (en) 1996-06-05
NZ332010A (en) 2000-02-28
EP1619186B1 (en) 2010-04-21
ES2370760T3 (en) 2011-12-22
ES2243988T3 (en) 2005-12-01
ATE465154T1 (en) 2010-05-15
PL329068A1 (en) 1999-03-15
ATE299867T1 (en) 2005-08-15
SK131698A3 (en) 2000-04-10
AU2162697A (en) 1997-10-17
PT1619186E (en) 2010-06-04
NO984487D0 (en) 1998-09-25
NO984487L (en) 1998-11-26
EP2143715B1 (en) 2011-09-21
SK285363B6 (en) 2006-11-03
EP1619186A1 (en) 2006-01-25
CZ295002B6 (en) 2005-05-18
PT2143715E (en) 2011-10-11
HU227541B1 (en) 2011-08-29
ATE525361T1 (en) 2011-10-15
NO312193B1 (en) 2002-04-08
JP4179630B2 (en) 2008-11-12
PL190574B1 (en) 2005-12-30

Similar Documents

Publication Publication Date Title
WO1997035841A3 (en) Method for obtaining pure enantiomers of a pyridazinone derivative
IL114028A0 (en) A method for obtaining pure enantiomers of 6-(4-amino-phenyl)-5- methyl-pyridazin 3(2H) one
CA2037098A1 (en) Hexahydrobenz ¢cd! indoles and processes for preparation thereof
EA200200100A1 (en) METHOD OF TREATMENT OR PREVENTION OF VASOSPASM CORONARY TRANSPLANT
AU2001272598A1 (en) A method for treating septic shock
AU2002251535A1 (en) Crystal of 6-(4-(4-pyridylamino)phenyl)-4, 5-dihydro-3(2h)-pyridazinone hydrochloride trihydrate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BA BG BR CA CN CZ EE GE HU IL IS JP KR LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US UZ AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BA BG BR CA CN CZ EE GE HU IL IS JP KR LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US UZ AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: PV1998-3041

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 332010

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 131698

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2250062

Country of ref document: CA

Ref document number: 2250062

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/007851

Country of ref document: MX

Ref document number: 1998/01921

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1997914347

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997914347

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09155294

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV1998-3041

Country of ref document: CZ

Ref document number: PV2002-1283

Country of ref document: CZ

Ref document number: PV2002-1282

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PV2002-1283

Country of ref document: CZ

Ref document number: PV2002-1282

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1998-3041

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 50352005

Country of ref document: SK

WWG Wipo information: grant in national office

Ref document number: PV2002-1282

Country of ref document: CZ

Ref document number: PV2002-1283

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1997914347

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 50042006

Country of ref document: SK